MEP57708A - Factor viia inhibitors - Google Patents

Factor viia inhibitors

Info

Publication number
MEP57708A
MEP57708A MEP-577/08A MEP57708A MEP57708A ME P57708 A MEP57708 A ME P57708A ME P57708 A MEP57708 A ME P57708A ME P57708 A MEP57708 A ME P57708A
Authority
ME
Montenegro
Prior art keywords
factor viia
compounds
formula
present
viia inhibitors
Prior art date
Application number
MEP-577/08A
Other languages
English (en)
Croatian (hr)
Inventor
Otmar Klingler
Manfred Schudok
Gerhard Zoller
Elisabeth Defossa
Hans Matter
Pavel Safar
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of MEP57708A publication Critical patent/MEP57708A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Ovaj pronalazak se odnosi na jedinjenja formule (I) u kojoj R1, R2, R91, R92, 93, R94,R95,R96,R97,r, s i t imaju značaje kako je naznačeno u zahtjevima. Jedinjenje formule (I) su vrijedna farmakološki aktivna jkedinjenja. Ona pokazuju jak antitrombotski efekat i podesna su, na primjer, za terapiju i profilsku tromboembolnih oboljenja ili restenoza. Ona su reversibilni inhibitori faktora enzima zgrušavanja krvi VIIa i mogu se gerneralno upotrebiti u uslovima koji su u kojima je neželjana aktivnost faktora VIIa prisutna ili za liječenje ili prevenciju gdje je namijenjena inhibicijas faktora VIIa. Pronalazak se dalje odnosi na postupke za dobijanje jedinjenja formule I, njihovo korišćenje, naročito kao aktivnih sastojaka kod farmaceutikala, i na farmaceutske preparate koje ih sadže.
MEP-577/08A 1999-06-08 2000-05-27 Factor viia inhibitors MEP57708A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99111109A EP1059302A1 (en) 1999-06-08 1999-06-08 Factor VIIa inhibitors
YUP-861/01A RS50415B (sr) 1999-06-08 2000-05-27 Inhibitori faktora viia
PCT/EP2000/004846 WO2000075172A2 (en) 1999-06-08 2000-05-27 FACTOR VIIa INHIBITORS

Publications (1)

Publication Number Publication Date
MEP57708A true MEP57708A (en) 2011-05-10

Family

ID=8238315

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-577/08A MEP57708A (en) 1999-06-08 2000-05-27 Factor viia inhibitors

Country Status (32)

Country Link
US (1) US6500803B1 (bs)
EP (2) EP1059302A1 (bs)
JP (1) JP4546683B2 (bs)
KR (1) KR100979069B1 (bs)
CN (1) CN1359390B (bs)
AR (1) AR024292A1 (bs)
AT (1) ATE246707T1 (bs)
AU (1) AU774037B2 (bs)
BR (1) BR0011461A (bs)
CA (1) CA2376064C (bs)
CZ (1) CZ300365B6 (bs)
DE (1) DE60004363T2 (bs)
DK (1) DK1189929T3 (bs)
EE (1) EE04855B1 (bs)
ES (1) ES2202137T3 (bs)
HK (1) HK1047289B (bs)
HR (1) HRP20010912B1 (bs)
HU (1) HUP0201451A3 (bs)
IL (2) IL146731A0 (bs)
ME (1) MEP57708A (bs)
MX (1) MXPA01012568A (bs)
NO (1) NO328249B1 (bs)
NZ (1) NZ515966A (bs)
PL (1) PL202879B1 (bs)
PT (1) PT1189929E (bs)
RS (1) RS50415B (bs)
RU (1) RU2248359C2 (bs)
SI (1) SI1189929T1 (bs)
SK (1) SK286902B6 (bs)
TR (1) TR200103550T2 (bs)
WO (1) WO2000075172A2 (bs)
ZA (1) ZA200110053B (bs)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1059302A1 (en) * 1999-06-08 2000-12-13 Aventis Pharma Deutschland GmbH Factor VIIa inhibitors
DE10005631A1 (de) * 2000-02-09 2001-08-23 Max Planck Gesellschaft Arginin-Mimetika als Faktor X¶a¶-Inhibitoren
GB0014134D0 (en) * 2000-06-10 2000-08-02 Astrazeneca Ab Combination therapy
EP1364960A4 (en) * 2001-02-02 2005-05-18 Chugai Pharmaceutical Co Ltd PEPTIDE DERIVATIVES
GB0127615D0 (en) * 2001-07-09 2002-01-09 Aventis Pharm Prod Inc Substituted amides, sulfonamides and ureas useful for inhibiting kinase activity
CA2536144C (en) 2003-08-18 2010-09-14 H. Lundbeck A/S Succinate and malonate salt of trans-4-(ir,3s)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and the use as a medicament
TWI453198B (zh) 2005-02-16 2014-09-21 Lundbeck & Co As H 製造反式-1-((1r,3s)-6-氯基-3-苯基茚滿-1-基) -3 , 3 -二甲基六氫吡與其鹽類之方法及製造4-((1r , 3s）-6 -氯基-3-苯基茚滿-1-基 )-1,2,2-三甲基六氫吡與其鹽類之方法
TWI376373B (en) 2005-02-16 2012-11-11 Lundbeck & Co As H Crystalline base of a pharmaceutical compound
DE602006011752D1 (de) * 2005-06-24 2010-03-04 Bristol Myers Squibb Co Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate
WO2007131996A1 (en) * 2006-05-12 2007-11-22 Genmedica Therapeutics Sl Meta-xylylenediamine vanadate salts
SI3464336T1 (sl) 2016-06-01 2022-06-30 Athira Pharma, Inc. Spojine
JP2022538674A (ja) 2019-07-01 2022-09-05 トニックス ファーマ リミテッド 抗ｃｄ１５４抗体およびその使用
MX2023008055A (es) 2021-01-06 2023-08-22 Tonix Pharma Ltd Métodos para inducir tolerancia inmune con anticuerpos anti-cd154 modificados.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023236A (en) * 1988-04-07 1991-06-11 Corvas, Inc. Factor VII/VIIA active site inhibitors
US5506134A (en) 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
US5788965A (en) 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
US5833982A (en) 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
SE9301916D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
DE69532754T2 (de) * 1994-04-26 2005-03-10 Aventis Pharmaceuticals, Inc. Faktor xa inhibitoren
PT892780E (pt) * 1996-02-22 2003-02-28 Bristol Myers Squibb Pharma Co Analogos de m-amidino fenilo como inibidores do factor xa
AR013084A1 (es) * 1997-06-19 2000-12-13 Astrazeneca Ab Derivados de amidino utiles como inhibidores de la trombina, composicion farmaceutica, utilizacion de dichos compuestos para la preparacion demedicamentos y proceso para la preparacion de los compuestos mencionados
EP0987274A1 (en) * 1998-09-15 2000-03-22 Hoechst Marion Roussel Deutschland GmbH Factor VIIa Inhibitors
EP1059302A1 (en) * 1999-06-08 2000-12-13 Aventis Pharma Deutschland GmbH Factor VIIa inhibitors

Also Published As

Publication number Publication date
PL352200A1 (en) 2003-08-11
PL202879B1 (pl) 2009-07-31
HUP0201451A3 (en) 2003-08-28
WO2000075172A3 (en) 2001-05-31
EP1189929B1 (en) 2003-08-06
US6500803B1 (en) 2002-12-31
ES2202137T3 (es) 2004-04-01
EP1059302A1 (en) 2000-12-13
DE60004363D1 (de) 2003-09-11
IL146731A (en) 2007-07-24
YU86101A (sh) 2004-07-15
EE200100662A (et) 2003-04-15
HK1047289A1 (en) 2003-02-14
SK17592001A3 (sk) 2002-05-09
NO20016005L (no) 2002-02-06
KR100979069B1 (ko) 2010-08-31
IL146731A0 (en) 2002-07-25
SK286902B6 (sk) 2009-07-06
RU2248359C2 (ru) 2005-03-20
HUP0201451A2 (en) 2002-08-28
CZ300365B6 (cs) 2009-04-29
CN1359390B (zh) 2010-05-26
ZA200110053B (en) 2002-07-03
CN1359390A (zh) 2002-07-17
BR0011461A (pt) 2002-03-19
NO328249B1 (no) 2010-01-18
AU774037B2 (en) 2004-06-17
CA2376064A1 (en) 2000-12-14
JP4546683B2 (ja) 2010-09-15
RS50415B (sr) 2009-12-31
SI1189929T1 (en) 2004-02-29
AU5397600A (en) 2000-12-28
DK1189929T3 (da) 2003-11-24
WO2000075172A2 (en) 2000-12-14
TR200103550T2 (tr) 2002-05-21
AR024292A1 (es) 2002-09-25
NO20016005D0 (no) 2001-12-07
HK1047289B (zh) 2010-10-22
NZ515966A (en) 2003-09-26
CZ20014357A3 (cs) 2002-03-13
DE60004363T2 (de) 2004-06-24
CA2376064C (en) 2011-04-26
MXPA01012568A (es) 2002-04-10
HRP20010912B1 (en) 2010-10-31
KR20020020728A (ko) 2002-03-15
PT1189929E (pt) 2003-12-31
ATE246707T1 (de) 2003-08-15
EP1189929A2 (en) 2002-03-27
HRP20010912A2 (en) 2003-04-30
EE04855B1 (et) 2007-06-15
JP2003502294A (ja) 2003-01-21

Similar Documents

Publication Publication Date Title
MEP43008A (en) Indole-2-carboxamides as factor xa inhibitors
PT1349847E (pt) Novos derivados de oxibenzamidas como inibidores do factor xa
EE03435B1 (et) Maatriksmetalloproteaasi inhibeeriva aktiivsusega ühendid, nende valmistamismeetodid ja kasutamine, vaheprodukt ja kompositsioon
MEP57708A (en) Factor viia inhibitors
IS7925A (is) Hýdroxýetýlamínafleiður til að meðhöndla Alzheimers-sjúkdóm
BRPI0208811B8 (pt) derivados de pirazol, seu uso e processo de preparação, bem como composição farmacêutica compreendendo os mesmos
DK0559743T3 (da) Nye hydroxamsyre- og N-hydroxyurinstofderivater og deres anvendelse
TR200101903T2 (tr) Yeni malonik asit türevleri, bunların preparasyon işlemleri.
YU89202A (sh) Faktor viia inhibitorni derivati (tio)uree, njihovo dobijanje i upotreba
HUP0100558A2 (hu) S-Oxid- és S,S-dioxid-tetrahidrotiopirán-fenil-oxazolidinon-származékok, e vegyületek alkalmazása gyógyászati készítmények előállítására, valamint eljárás e vegyületek gátló hatásának meghatározására humán-monoamin-oxidázzal szemben
DE60214569D1 (de) Harnstoffverbindungen mit antiproteolytischer wirkung
BR0115938A (pt) Derivados de guanidina e amidina com inibidores do fator xa
YU29702A (sh) N-gvanidinoalkilamidi, njihovo dobijanje, njihova primena i farmaceutski preparati koji ih obuhvataju
ATE322244T1 (de) Verwendung von polyaminosäurederivaten zur behandlung von seborrhoe und verwandten hautstörungen
HUP0402241A2 (hu) Metformin és 4-oxo-butánsav kombinációját tartalmazó gyógyászati készítmény, és a készítmény alkalmazása diabétesz kezelésére
TW200716620A (en) Heteroaryl-carboxylic acid (sulfamoyl alkyl) amide-derivatives as factor Xa inhibitors
DE60321700D1 (de) Pyrazolderivate und deren verwendung als therapeutische mittel für durch hiv vermittelte krankheiten
TH55701A (th) อนุพันธ์ 1,2-ไดเฟนิลพิโรล, การเตรียมสารเหล่านี้และการใช้สารเหล่านี้ในการรักษาโรค